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Abstract
Background: Given the persistent shortage of organs for transplantation, new donor management strategies to
improve both organ utilization and quality of procured organs are needed. Current management protocols for the
care of the deceased donor before organ procurement are based on physiological rationale, experiential reasoning,
and retrospective studies without rigorous testing. Although many factors contribute to the lack of controlled
clinical trials in donor management, a major factor is the unique challenges posed by research in the brain-dead
organ donor.
Methods and Results: This article describes the study design and the challenges faced during implementation of
the Beta-agonists for Oxygenation in Lung Donors (BOLD) study, a randomized, placebo-controlled clinical trial of
nebulized albuterol vs. placebo in 500 organ donors. The study design and implementation are described with
emphasis on aspects of the study that are unique to research in brain-dead organ donors.
Conclusions: Experience gained during the design and implementation of the BOLD study should be useful for
investigators planning future clinical trials in the brain-dead donor population and for intensivists who are involved
in the care of the brain-dead organ donor.
Introduction
Despite recent efforts to improve donation awareness,
family consent, clinical management, and organ utiliza-
tion, there remains a persistent shortage of organs for
transplantation [1] and a plateau in the number of
organ donors has been noted. Thus, new strategies to
improve the quality of donated organs and rates of
organ utilization are still needed. An important strategy
to improve organ utilization is through novel donor
management therapies that are designed to optimize
organ function in the deceased donor, thus maximizing
the likelihood of organ utilization and minimizing the
likelihood of graft dysfunction.
New donor management therapies should be rigor-
ously evaluated before clinical implementation. Rando-
mized, controlled, clinical trials are the primary route
for testing of new pharmacologic therapies and other
clinical interventions in living patients. However, there
have been very few randomized, clinical trials in
deceased donor management [2]. Current management
protocols for the care of the organ donor before organ
procurement are based on physiological rationale,
experiential reasoning, and retrospective studies without
the benefit of rigorous testing [3]. Although there are
many factors that contribute to the lack of controlled
clinical trials in donor management, a major factor is
the unique challenges posed by research in the brain-
dead organ donor.
To advance the field of donor management and opti-
mize organ utilization, there is a pressing need to apply
the science of clinical trial design to the implementation
of donor management studies. The purpose of this arti-
cle is to describe the study design and the challenges
faced during implementation of the Beta-agonists for
Oxygenation in Lung Donors (BOLD) (NCT #00310401)
study, a trial of nebulized albuterol vs. placebo in 500
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organ donors. We have placed particular emphasis on
aspects that are unique to conducting research in brain-
dead organ donors. Experience gained during the design
and implementation of the BOLD study should be useful
for investigators planning future clinical trials in the
brain-dead donor population.
Study rationale
The demand for lung transplantation exceeds the supply
of donor lungs, leading to protracted waiting times and
a high death rate on the waiting list [4-6]. Although the
use of extended donors who do not meet traditional cri-
teria for lung donation has improved donor lung utiliza-
tion rates at selected centers [7-10], the national donor
lung utilization rate remains low [4]. The most common
reasons for failure to utilize donor lungs are donor
hypoxemia and/or pulmonary infiltrates [4]. Acute pul-
monary edema occurs commonly in association with
acute brain injury [4] and is a potentially reversible
cause of donor hypoxemia and pulmonary infiltrates. In
lungs from 29 donors that were rejected for transplanta-
tion, lung wet-to-dry weight ratio, a measure of pulmon-
ary edema, was normal in only 7 (24%), indicating that
pulmonary edema is very common in organ donors [11].
Strategies to enhance the resolution of pulmonary
edema could lead to improved donor oxygenation and
higher rates of donor lung utilization.
The clearance of pulmonary edema fluid from the dis-
tal airspaces is driven by active transport of sodium
across the alveolar epithelium [12]. Faster rates of alveo-
lar fluid clearance are associated with more rapid
improvements in oxygenation in patients with hydro-
static pulmonary edema [13] and better oxygenation, a
shorter duration of mechanical ventilation, and
improved survival in patients with acute lung injury
[14,15]. In addition, in recipients with primary graft dys-
function and reperfusion pulmonary edema after lung
transplantation, those with intact alveolar fluid clearance
had more rapid improvements in oxygenation than reci-
pients with impaired fluid clearance [16]. Thus, the
capacity to resolve alveolar edema is an important vari-
able in determining clinical outcomes across a wide vari-
ety of critically ill patients with acute pulmonary edema.
Inhaled beta-2 agonists increase the rate of alveolar
fluid clearance and reduce pulmonary edema in both
animal and human lungs [12]. In donor lungs that were
excised but not transplanted, the majority responded to
beta-2 adrenergic agonists instilled into the airspaces
with increased rates of alveolar fluid clearance [11,17].
Standard doses of inhaled beta-2 agonists reach concen-
trations in the pulmonary edema fluid that are sufficient
to stimulate alveolar fluid clearance [18]. Based on this
evidence, we hypothesized that pharmacologic treatment
with an inhaled beta-2 adrenergic agonist to enhance
clearance of pulmonary edema from the distal airspaces
would reduce donor hypoxemia and increase donor lung
utilization. To test this hypothesis, we designed a pro-
spective, randomized, clinical trial to test the efficacy of
inhaled albuterol to increase the rate of alveolar fluid
clearance and reduce pulmonary edema in brain-dead
organ donors.
Study overview
The BOLD study is a multicenter, randomized, double-
blind, placebo-controlled trial that compared the effects of
nebulized albuterol to placebo on donor oxygenation in
500 brain-dead organ donors. The coordinating center for
the trial is at Vanderbilt University. Donors are enrolled at
175 hospitals served by the California Transplant Donor
Network (CTDN), an organ procurement organization
that serves a population of more than 10 million people in
Northern California and parts of Nevada (Figure 1). The
trial is funded by the National Institutes of Health through
the National Heart Lung and Blood Institute and enrolled
its first donor in April 2007.
Clinical and physiological endpoints
Primary outcome
Study outcomes are summarized in Table 1 and Figure 2.
The primary outcome is the change in donor oxygenation
from enrollment to organ procurement. This is defined
as the change in the PaO2/FiO2 ratio as measured by
arterial blood gas analysis from enrollment to organ pro-
curement or 72 hours, whichever occurs first. In addition
to the overall change in PaO2/FiO2, the change in the
area under the curve for all measurements of PaO2/FiO2
will be evaluated.
Secondary clinical outcomes
The effect of albuterol on several secondary clinical out-
comes will be evaluated (Table 1), including the donor
lung utilization rate, the change in static lung compli-
ance from enrollment to organ procurement, and the
change in chest radiographic score from enrollment to
organ procurement.
Recipient outcomes Lung and other solid organ recipi-
ent outcomes will be analyzed as secondary outcomes,
including 30-day graft and recipient survival.
Secondary physiologic outcomes
Lungs that are not used for clinical transplantation are
resected without perfusion and transported to the
BOLD Lung Physiology Laboratory at UCSF for physio-
logic evaluation, including measurement of the lung
wet-to-dry weight ratio and the rate of alveolar fluid
clearance [17].
Selection of study subjects
The inclusion and exclusion criteria are intended to
maximize enrollment. We considered excluding donors
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in whom there is an absolute contraindication to lung
transplantation (such as serious preexisting lung dis-
ease), because the secondary outcome of donor lung uti-
lization could not be improved by albuterol treatment in
this group. However, because the primary outcome
(donor oxygenation) could theoretically be improved by
albuterol in all donors, and contraindications to lung
transplantation are not always apparent at the beginning
of the donor management period, we chose to include
all donors. All brain-dead organ donors managed by the
Figure 1 Geographic area in Northern California served by the California Transplant Donor Network (shaded area). Northern Nevada
also is served by the California Transplant Donor Network.
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CTDN who are 14 years of age or older and have next-
of-kin consent for organ donation and research are eligi-
ble for enrollment in the clinical arm of the study. For
inclusion in the secondary physiologic outcomes arm of
the study, the lungs also must be rejected for transplan-
tation and approved for research use by the coroner or
medical examiner. For inclusion in the secondary phy-
siologic outcomes arm of the study, a qualified surgeon
must be available to resect the lungs at the time of
organ procurement.
In addition to the above-mentioned inclusion criteria,
for a donor to be included in the final analysis, they
must receive at least one dose of study drug and com-
plete the donation process as defined by surgical pro-
curement of at least one organ. Five to ten percent of
donors managed by the CTDN do not complete the
organ donation process usually due to severe hemody-
namic instability and/or multiorgan system failure.
Because these donors are typically managed for less
than 12 hours, they would be unlikely to receive more
Table 1 Primary and secondary outcomes for the BOLD study
Type of outcome Outcome Definition
Primary Donor oxygenation Change in the PaO2/FiO2 ratio as measured by arterial blood gas analysis from enrollment to
organ procurement or 72 hours, whichever occurs first
Secondary clinical Donor lung
utilization rate
The number of lungs transplanted divided by the total number of lungs available in the
donors enrolled in each study arm. The donor utilization rate will also be evaluated using
only potentially transplantable lungs in the denominator. For this analysis, donors whose
lungs have absolute contraindications to transplantation will not excluded including donors
with (1) significant pulmonary disease, (2) bilateral lung contusion, (3) hepatitis C antibody
positive (4) age over 65 years or (5) HIV positive.
Static lung
compliance
Change in static lung compliance between enrollment and organ procurement or 72 hours,
whichever occurs first. During study enrollment, static lung compliance is measured every 12
hours and immediately prior to organ procurement.
Chest radiographic
score
Change in chest radiographic pulmonary edema score between enrollment radiograph and
radiograph obtained just prior to organ procurement. Chest radiographs are scored in a
blinded fashion by two of the investigators using a scoring system developed and validated
specifically for this study [29].
Secondary physiological
(only in lungs that are not used
for transplantation)
Lung wet-to-dry
weight ratio
Gravimetric measurement of the ratio of the wet weight compared to the lung weight after
drying. The lung wet-to-dry weight ratio is a quantitative index of the degree of pulmonary
edema [17]. Total lung weight will also be measured.
Rate of alveolar
fluid clearance
The rate of alveolar fluid clearance is measured in a rewarmed lobe of the excised lung after
instillation of an isotonic albumin-containing solution [17]
Secondary recipient
(only in lung transplant
recipients)
30-day lung graft
survival
Percent of lung allografts that are functional 30 days after transplantation in each study arm
30-day lung
recipient survival
Percent of lung transplant recipients that are alive at 30 days after transplantation in each
study arm
Figure 2 Summary of clinical and physiological outcomes in the BOLD study.
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than one or two doses of the study drug and would have
an inadequate time period over which to be assessed for
the primary and secondary outcomes.
Consent process
The complex ethical issues that arise in donor manage-
ment clinical trials were the subject of a recent review
[19] and will not be considered in detail here. Under
United States federal regulations, brain-dead organ
donors are not legally considered to be human subjects
for the purposes of informed consent. For this reason,
the consent process for the BOLD study has been tai-
lored for the donor population. At the time that a
CTDN representative meets with family members of the
deceased to obtain consent for organ donation, consent
for research, including donor management studies, also
is discussed. If the family member consents for research,
then the donor becomes eligible for enrollment in the
BOLD study.
Regarding consent from lung transplant recipients
who will receive lungs from donors enrolled in the
study, a panel of consulting transplant bioethicists have
concurred that informed consent from lung recipients is
not required in the BOLD study, because the study
poses minimal risk, it has traditionally been the role of
the transplant surgeon to determine the relative risk of
an organ, and finally, there is no precedent in the trans-
plant community for requiring recipient consent for
donor management studies that pose minimal risk.
Treatment groups and randomization
There are two treatment groups. The albuterol group
receives 5.0 mg of albuterol by nebulization every 4
hours from the time of study enrollment until organ
procurement. The placebo group receives an equivalent
volume of nebulized saline every 4 hours.
Subjects are prospectively randomized in a 1:1 ratio
among study and placebo groups. Randomization is con-
ducted by the UCSF Investigational Pharmacy. The
Investigational Pharmacy prepares study drug and pla-
cebo in identical vials that are randomly assigned study
numbers in permuted blocks of eight. Sufficient study
drug for one donor is placed in individual donor study
kits that are distributed to the CTDN Transplant Coor-
dinators for use when a donor is enrolled in the study.
Each Transplant Coordinator maintains a stock of these
kits so that a kit is always available when a Transplant
Coordinator is on site at any of the 175 hospitals served
by the CTDN. Each study subject is assigned a number
that corresponds to the number on the study drug vial
as part of the randomization process, and the number
becomes that subject’s unique treatment number.
Blinding of the study drug is preserved throughout
the study. No treatment group information is provided
to the investigators or CTDN staff except in case of
an emergency, and a log of unblinding events is
maintained.
Study procedures
The study flow is summarized in Figure 3. All study
procedures and primary data collection is performed by
the CTDN Transplant Coordinators who are responsible
for the clinical management of the organ donor onsite
at the hospital. Enrollment into the BOLD study occurs
once the CTDN assumes clinical care of the brain-dead
patient with consent for organ donation and research
and upon meeting inclusion and exclusion criteria. Neb-
ulized study drug (albuterol or identical saline placebo)
is administered every 4 hours by using a standard nebu-
lizer device provided in the individual donor study kit
for 72 hours or until the donor is sent to the operating
room for organ procurement, whichever occurs first.
Arterial blood gas, static lung compliance, and chest
radiograph are obtained before the first dose of study
drug and immediately before organ procurement for
assessment of the primary and secondary study end-
points. Donors are managed using standard CTDN pro-
tocols [20] except for the administration of study drug
and data collection, with one exception. It is recom-
mended that all donors enrolled in the BOLD study be
ventilated with 10 cc/kg of tidal volume based on pre-
dicted body weight to minimize ventilator-associated
lung injury [21]. However, ventilator settings remain at
the discretion of the Transplant Coordinator and super-
vising Advanced Practice Coordinator and may be
altered depending on the clinical circumstances.
Study variables
Comprehensive data are collected for each donor. At
enrollment, demographics, medical history, cause of
brain death, smoking, alcohol and drug use history, and
hospital course before brain death are recorded.
Throughout the study period, hemodynamic and ventila-
tory parameters are recorded hourly along with medica-
tion administration, fluid balance, and culture and test
results. At organ procurement, organ disposition for all
solid organs is recorded along with reasons for
nonallocation.
In addition to clinical data, blood is collected for
plasma and DNA at study enrollment. These blood sam-
ples are transported to an HLA typing laboratory at
UCSF by courier along with donor samples for HLA
typing. A second plasma sample is obtained at the time
of organ procurement and is transported to the UCSF
HLA laboratory by courier along with samples that are
collected from the donor for tissue banking. The HLA
laboratory processes all blood immediately to separate
plasma, which is frozen at -80C in small aliquots and
shipped to the coordinating center at Vanderbilt.
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Hard or digital copies of enrollment and procurement
chest radiographs are mailed to the coordinating center
at Vanderbilt where they are scored by two investigators
blinded to treatment arm assignment.
Sample size
The sample size was estimated using oxygenation data
obtained from the CTDN for donors managed by stan-
dard protocols. The targeted enrollment is 500 donors
who complete the organ donation process, 250 treated
with albuterol, and 250 treated with placebo. This sam-
ple size yields a power of 0.8 to detect an increase in
the primary outcome, donor oxygenation, expressed as
the mean difference of PaO2/FiO2, by 37.5 using a two-
sided, two-sample t-test with a significance level of 0.05.
The principal analysis will be intention-to-treat, based
on randomization assignment among donors who com-
plete the donation process and receive at least one dose
of study drug. Interim analyses are planned at sample
sizes of 100 and 300 for safety (see below) and efficacy.
Early stopping rules for efficacy are based on the
observed difference in PaO2/FiO2 ratio. Using stopping
rules described in Jennison and Turnbull [22], the p-
value thresholds are 7.4 × 10-6, 0.01, and 0.04 at the two
interim and the final analyses, respectively.
Data safety and monitoring
Safety considerations
In a large randomized trial of intravenous albuterol (sal-
butamol) in acute lung injury, the primary side effects
were tachycardia and cardiac arrhythmias [23]. In the
BOLD study, heart rate is monitored continuously. If
heart rate increases by > 30 bpm during the study drug
aerosolization, the aerosol is stopped. Because fluctua-
tions in heart rate may be multifactorial, the subject is
evaluated and a cause for tachycardia other than study
drug is sought and if identified, treated. The next
scheduled aerosolization of study drug is given at 5 mg
of albuterol or placebo, and if the heart rate increases
by > 30 bpm again, the aerosol is stopped and subse-
quent study drug doses are reduced to 2.5 mg (albuterol
or placebo). A subsequent increase in heart rate > 30
bpm results in the study drug being held for another 4
hours and restarted at the 2.5-mg dose. Any subsequent
increases in heart rate of > 30 bpm result in disconti-
nuation of study drug for the duration of the study.
In subjects developing sustained atrial or ventricular
arrhythmias, the study drug is discontinued and the
event is reported as an adverse event. Eligible subjects
with preexisting atrial fibrillation or multifocal atrial
rhythms with a controlled ventricular response may par-
ticipate in this trial. For enrolled subjects with preexist-
ing atrial fibrillation or multifocal atrial rhythms, study
drug is dosed and subsequently adjusted, held, or dis-
continued based on change in baseline heart rates as
previously described. If subjects develop more than four
new premature ventricular contractions (PVCs) per min-
ute during aerosolization of the study drug, then the
treatment is stopped for the remainder of the study.
Because several clinical studies show that inhaled beta-
2 agonists do not result in significant alterations in
blood pressure, we have not established specific guide-
lines for dose adjustments for blood pressure. Altera-
tions in blood pressure may be related to other clinical
events or pharmacologic interventions.
Data Safety and Monitoring Board
The Data Safety and Monitoring Board (DSMB) moni-
tors donor safety, protocol adherence, and data quality.
The DSMB receives reports of serious adverse events.
Interim safety analyses are performed after 100 and 300
patients to detect unexpected changes in lung
utilization.
Pearson’s chi-square test will be computed to assess
differences in lung utilization between treatment groups.
Figure 3 Timeline for study procedures in the BOLD study.
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Statistical significance will be judged based on the nom-
inal 0.05 level. If a difference in treatment groups is
determined, the DSMB will break the blind to assess the
nature of the observed difference, as well as other fac-
tors that might differ between groups (e.g., age, smoking
status). Because the study is minimal risk, there is no
plan for early stopping for futility.
Quality control
Because donors can be enrolled at any of the 175 hospi-
tals served by the CTDN, the study activities are per-
formed primarily by the transplant coordinators who are
at the bedside from before enrollment until after organ
procurement. CTDN transplant coordinators arrange for
the study drug to be administered by the hospital
respiratory therapist, draw blood samples, and record
study data. Transplant coordinators are a heterogeneous
group with different backgrounds (nursing, respiratory
therapy, emergency medical services), training, and
experience and typically have no formal training in
human research. All CTDN transplant coordinators
were trained extensively in the study procedures before
the study launch and refresher training is done fre-
quently. Study data are reviewed by the principal investi-
gator as they accrue, and all protocol violations are
immediately reported to the CTDN study coordinator
who contacts the respective transplant coordinator to
discuss the protocol violation and provide additional
training.
Study design and implementation challenges
Brain-dead donors are a unique patient population.
Implementing a randomized, controlled trial in donors
has led to many challenges, which are addressed below.
Ventilator management
Although a recent study suggests that lower tidal
volumes are superior to higher tidal volumes in the
management of the organ donor [24], standard proto-
cols in use by the CTDN at the start of the BOLD study
in 2007 dictated a tidal volume of at least 10 ml/kg of
actual body weight and PEEP of at least 5 mmHg with
further increases up to a maximum of 15 ml/kg man-
dated if PaO2 on FiO2 of 1.0 was < 500 and/or chest
radiograph was not clear. In addition, it was recom-
mended that tidal volumes should be set at the highest
possible range while maintaining peak inspiratory pres-
sures less than 30 cmH2O. This protocol was well estab-
lished for optimizing cardiopulmonary function and was
associated with lung utilization rates that were among
the highest nationally. However, because of the known
adverse effects of high tidal volume on lung inflamma-
tion [25,26] and alveolar fluid clearance [27], we were
concerned that these high tidal volumes might cause
sufficient lung injury in donors in the BOLD study to
render the lungs unable to respond to beta-adrenergic
agonist-mediated stimulation of alveolar fluid clearance.
Although we would have preferred to use the NHLBI
ARDsNet protective ventilatory strategy of 6 ml/kg of
tidal volume based on predicted body weight [28], this
preference had to be weighed against the CTDN priority
for optimizing inflation volumes to demonstrate good
lung function to promote lung utilization for transplan-
tation. A compromise was reached at 10 ml/kg of pre-
dicted body weight. This integration of predicted body
weight into the setting of tidal volume necessitated a
significant degree of staff reeducation.
Hospital Institutional Review Boards
Because brain-dead organ donors are not legally consid-
ered to be human subjects for the purposes of Institu-
tional Review, we did not seek approval from the
institutional review boards (IRBs) of the 175 hospitals
where a brain-dead donor enrolled in BOLD might be
cared for by the CTDN. The IRBs at the coordinating
center (Vanderbilt) and at the BOLD Lung Physiology
Laboratory site at UCSF both confirmed that the study
does not involve human subjects. However, in the
course of implementing the study, we have encountered
questions from several hospital IRBs when they have
become aware of the study, usually as a result of ques-
tions from hospital respiratory therapists who are asked
to administer the study drug. By request, the study has
been submitted and approved by several hospital IRBs.
One hospital declined to participate, although no reason
was given and the protocol had received IRB approval.
Another declined to participate because of a hospital
policy barring use of nebulized medications in mechani-
cally ventilated patients.
Correct study drug dosing
Study drug is supplied in a concentrated form that must
be diluted with saline for nebulization. On occasion,
errors by the hospital respiratory therapist have led to a
failure to dilute the study drug appropriately with subse-
quent administration of two to three times the pre-
scribed dose. To prevent this error, the BOLD study
drug vial label was redesigned to highlight the dilution
instructions. In addition, new procedures were put in
place to mandate face-to-face communication between
the transplant coordinator and the hospital respiratory
therapist before study initiation. This issue highlights
the challenge of implementing a clinical trial of a ther-
apy that must be administered by a respiratory therapist
to a donor whose care is managed by a transplant coor-
dinator but who is still an inpatient at one of 175 dispa-
rate hospitals.
Management of bronchospasm
Although bronchospasm is not a common problem in
organ donors, it does occur. To avoid reflexive open label
use of albuterol for any symptoms of bronchospasm, a
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protocol for management of bronchospasm was put into
place in the BOLD study such that decisions for manage-
ment of bronchospasm are made in consultation with an
Advanced Practice Coordinator. Use of alternative agents,
such as ipratropium bromide, is encouraged but not pro-
tocolized and use of any open-label albuterol is recorded
and requires a written explanation.
Protocol violations
The most common protocol violation has been failure to
obtain baseline study variables, such as arterial blood
gas, before study drug initiation. The transplant coordi-
nator has the difficult task of simultaneously optimizing
donor hemodynamics and organ function, arranging for
a variety of ancillary tests, assisting grieving families,
and assisting with organ allocation. The added work
burden of conducting a research study within the short
period of donor management can be challenging and
may not take precedence during very busy times.
Designing an intervention and case report from that
could be seamlessly integrated into the usual flow of
donor management was a challenge and ongoing rein-
forcement of the need to obtain baseline study variables
has been required.
Conclusions
To increase donor organ utilization, new donor manage-
ment therapies are needed to optimize donor organ
function. A randomized, clinical trial is the most reliable
method to test different donor management therapies.
Experience gained in the design and implementation of
the BOLD trial illustrates some of the challenges inher-
ent in donor research but also demonstrates that large,
randomized, clinical trials are feasible. It is our hope
that experience gained in the BOLD study will stimulate
other investigators to test donor interventions in rando-
mized, clinical trials in the donor population.
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